Novartis' Kymriah (Tisagenlecleucel) for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) in adults has been accepted for review by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively.

A team led by Yanhe Ma of Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences has designed and constructed an 11-step unnatural carbon sequestration and starch synthesis pathway from scratch in a similar way of "building blocks", and achieved the complete synthesis from carbon......

In plastics, it can improve the dimensional stability, hardness and rigidity of plastic products, and improve the processing performance of plastics and the heat resistance and astigmatism of their products.

Berzosertib (VX-970, M6620) is a first-of-its-kind, potent, selective ATR inhibitor developed by Merck. Ceralasertib (AZD6738) is a selective ATR inhibitor developed by astrazeneca with an IC50 of 1nM. BAY1895344 is a highly effective, highly selective oral ATR inhibitor developed by bayer wit......

Recently, Dr. Shao feng and Dr. Xiaoyun Liu of Peking University School of Basic Medical Sciences published an important new progress in the leading academic journal Nature, revealing a new mechanism by which pathogenic bacteria inhibit pyrodeath in host cells. This discovery adds another milestone ......

The Peking University research team has developed a specific drug for the treatment of COVID-19 and the mechanism of action of the specific drug DXP-604